A randomized, double-blind, placebo-controlled, multi-center Phase 1b study to evaluate the safety, efficacy and microbiological response of orally administered ABI-M201 in subjects with mildly-to-moderately active Ulcerative Colitis with ongoing Mesalamine treatment.